Breakthrough Agents Reshaping RRMM Treatment Landscape
Noa Biran, MD, reviews approved bispecific T-cell engagers and how they redefine multiple myeloma treatment, yielding high response rates in refractory cases, but their use necessitates careful evaluation in later therapy lines.
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
Now Viewing
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
EP: 4.Examining Selinexor Role in RRMM Treatment
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
Related Videos
